FIGURE 6 from B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

B7H3.CAR EBVSTs targets allogeneic monocytes and matured HSPCs but spares T, B, and NK cells as well as resting and early HSPCs. A, Cytolysis of allogenic T, NK, and B cells by UT and B7H3.CAR EBVSTs in the presence of various cytokines. Fold change in cell counts was calculated by normalizing allogeneic immune cell counts in presence of B7H3.CAR EBVSTs against that of UT EBVSTs. B, Percentage of death in allogeneic monocytes after 24 hours coculture at a 1:1 E:T ratio with UT or B7H3.CAR EBVSTs. C, B7-H3 expression on memory EBVSTs that have been reactivated with antigen-presenting cells pulsed with EBV, HIV, or no peptides. D, Flow plots representing B7-H3 expression in HSPC populations after the indicated days of stimulation with Flt3L, TPO, and SCF. E, Cytotoxicity of unstimulated and stimulated HSPCs after coculture with UT or B7H3.CAR EBVSTs. F, Erythroid and myeloid development potential of HSPCs alone, after coculture with UT or B7H3.CAR EBVSTs. Data in A and C are compiled from UT and B7H3.CAR EBVSTs generated from 3 donors cocultured with PBMCs or monocytes isolated from 3 other different donors. Data presented in C are representative of B7-H3 expression on reactivated EBVSTs from 2 donors. Data in D–F are compiled from UT and B7H3.CAR EBVSTs generated from 3 donors cocultured with HSPCs isolated from 2 other different donors. For B, groups were compared using Student unpaired t test. For F, groups were compared using one-way ANOVA with Tukey test for multiple comparisons test. *, P P P